Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pfizer Presents Phase 3 Safety And Immunogenicity Data On HIV Drug

Published: Tuesday, March 05, 2013
Last Updated: Tuesday, March 05, 2013
Bookmark and Share
Pfizer Inc. presented the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13® in adults infected with HIV.

The results were presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, Ga.

These data support planned regulatory submissions seeking to include data on HIV-infected immunocompromised adults in the Prevnar 13 label in the United States, the European Union, and other countries around the world.

In this study, HIV-infected individuals aged 18 years and older who had been previously vaccinated with at least one dose of the conventional pneumococcal polysaccharide vaccine (PPSV) received three doses of Prevnar 13 given six months apart. An immune response to the serotypes in the vaccine was observed after the first dose of Prevnar 13, and each of the two subsequent doses. The clinical relevance of the level of response is not known. The most common local reaction at the injection site was pain and the most common adverse event after vaccination was headache. Adverse events were generally consistent with those expected in this study population.

“Modern advances in medicine have significantly improved HIV case management, but the threat of infectious diseases to those with weakened immune systems is still prevalent,” said Dr. Raul Isturiz, Pfizer Medicine Development Group and Scientific Affairs, Vaccines. “In fact, people living with HIV are more susceptible to the potentially devastating effects of pneumococcal diseases.”
For adults with HIV, the incidence of invasive pneumococcal disease is significantly higher and the potential of recurrent disease, most of which represents re-infection, is more likely to occur in these individuals.

“These data add to the compelling body of research for Prevnar 13,” said Dr. William Gruber, senior vice president, Pfizer Vaccine Clinical Research and Development. “Pfizer is committed to providing information about this important vaccine across all age groups, especially those with conditions that put them at higher risk of pneumococcal infections, such as those with HIV infection.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pfizer's $14Bn Acquisition of Medivation
It has been announced that Pfizer will acquire Medivation for $81.50 a share for a total value of roughly $14 billion.
Tuesday, August 23, 2016
Pfizer, Western Oncolytics Research Collaboration
Pfizer and Western Oncolytics have announced an immuno-oncology research collaboration.
Friday, July 29, 2016
Pfizer's $40M Bid for BIND Therapeutics
BIND Therapeutics announced Pfizer's $40 million winning bid at a Section 363 asset auction.
Thursday, July 28, 2016
Pfizer Advances Biosimilars Leadership with Investment in Biotechnology Center
Company has announced that the facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reforms.
Tuesday, June 28, 2016
Pfizer Breaks Ground On New Biologics Facility
The company has broken ground for its new biologics clinical manufacturing facility in Andover, Massachusetts.
Monday, June 20, 2016
Pfizer Terminates $160bn Allergan Deal
Proposed merger agreement between Pfizer and Allergan has been terminated by mutual agreement of the companies.
Wednesday, April 06, 2016
Pfizer, Calibr Collaborate
The California Institute for Biomedical Research (Calibr), a nonprofit translational research institute, has announced that it has entered into a global strategic collaboration with Pfizer Inc. to develop novel antibody-based therapeutic agents for the treatment of heart failure.
Friday, January 15, 2016
Pfizer CTI, Foundation Launch Collaboration
Pfizer’s Centers for Therapeutic Innovation (CTI) and the Jeffrey Modell Foundation (JMF) have agreed to collaborate intended to advance research into immunological diseases.
Thursday, July 09, 2015
Pfizer Enters into Agreement with GlaxoSmithKline
Agreement with GSK to acquire Nimenrix and Mencevax vaccines.
Thursday, June 25, 2015
Pfizer Acquires Minority Interest in AM-Pharma
Option to acquire company may be exercised based on Phase II trial results for recombinant human Alkaline Phosphatase.
Tuesday, May 12, 2015
Pfizer to Acquire Hospira for $17B
Companies have into a definitive merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion.
Thursday, February 05, 2015
Pfizer Acquires Redvax
Acquisition provides Pfizer with a preclinical CMV vaccine candidate.
Thursday, January 08, 2015
Pfizer to Acquire InnoPharma
Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.
Wednesday, July 16, 2014
Pfizer Maneuvers to Protect Lipitor from Generics
Lipitor is so valuable that Pfizer is practically paying people to keep taking its blockbuster cholesterol medicine after generic competition hit the U.S. market last week.
Tuesday, December 06, 2011
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!